Two compounds interfering with LPS‐TLR4 signalling have been used in clinical trials: Eritoran (also known as E5564) and Resatorvid (also known as TAK‐242); however, none have focused specifically on SI‐AKI. The gene discussed is TLR4; the disease is acute kidney injury.